28 March 2019

Diagnosing Parkinson's is not easy. In particular in the early stages, it can be difficult to distinguish Parkinson's from a group of other disorders that at first sight look identical. In Annals of Neurology, researchers from Radboud umc and the University of Edinburgh describe a new biomarker that can quickly and reliably indicate whether someone has Parkinson's or not.

In a typical patient with Parkinson's disease, there is usually little doubt about the diagnosis. However, many patients display less typical symptoms. In this group, certainly in the early stages of the disease, it can be difficult to distinguish Parkinson's from a group of other disorders that at first sight look identical. There is a large group of other disorders within the Parkinson's spectrum that have overlapping symptoms, such as progressive supranuclear gaze palsy (PSP), parkinsonism as a result of medication use and vascular parkinsonism. This often leads to years of searching: after twelve years, ten percent of these patients still do not have a clear diagnosis! This leads to a great deal of uncertainty for patients, makes treatment less goal-oriented, and hinders scientific research.

Useful biomarkers

Researchers from Radboud umc and the University of Edinburgh have started looking for useful biomarkers that can shorten this search. Biomarkers are products in the metabolism that are very characteristic of a certain disease. Alpha-synuclein is such a substance. If this protein is folded incorrectly (misfolded), it has a stick-on effect. Other alpha-synucleins stick to it, creating protein cables (fibrils) that are characteristic of Parkinson's disease. These protein cables are absent in many other forms of parkinsonism.
In some people with an unclear form of Parkinson's disease, this misfolded protein can be detected at an early stage. That finding means that a patient almost certainly has Parkinson's.

More clarity

Marcel Verbeek from the Department of Neurology: “We have observed many people within the Parkinson spectrum. We have collected clinical data, DNA, body fluids and all kinds of other data. Together with the researchers from Edinburgh, who came up with the alpha-synuclein test, we checked whether the test worked for more than one hundred patients and fifty control subjects.” The results have now been published in Annals of Neurology. In more than eighty percent of patients with an unclear diagnosis, this test enabled physicians to reliably determine whether or not the patient had Parkinson's. Verbeek: “This test can make a very valuable contribution to the diagnosis of people with an unclear form of Parkinson's disease.”

Lighting up?

The test uses cerebrospinal fluid that is collected from the patient through a spinal puncture. But how can you determine whether this fluid contains misfolded alpha-synucleins? “Because of the extremely low concentration, they are difficult to demonstrate,” says Verbeek. “That's why we add a high concentration of well-folded proteins. This creates a domino effect: if misfolded alpha-synucleins are present in the patient's cerebrospinal fluid, they will also misfold the good proteins. When this happens, they will light up, because this activity activates a fluorescent substance. If light is generated, then there are misfolded alpha-synucleins present in the cerebrospinal fluid, and the patient probably has Parkinson's disease. If the proteins do not light up, the patient doesn't have Parkinson's disease, but another form of parkinsonism.”

Valuable addition

The new test with this biomarker can contribute, at an early stage, to more clarity for the group of patients without a completed diagnosis. “This is very important for patients who are sometimes in the dark about what ails them for ten years or longer,” says Verbeek. “A clear diagnosis also provides more information about the further progression of the disease, and the use of medication. If this test also yields good results in other research groups, it can be a valuable addition to Parkinson's diagnostics.”
 
Publication:
Alpha-synuclein RT-QuIC in the CSF of uncertain cases of parkinsonism
Anouke van Rumund, Alison JE Green, Graham Fairfoul, Rianne AJ Esselink, Bastiaan R Bloem, Marcel M Verbeek.
Annals of Neurology
 

Related news items


Laurens Verscheijden awarded doctorate degree 'cum laude'

19 January 2022

Laurens Verscheijden of the Department of Pharmacology and Toxicology, defended his PhD thesis, entitled "Mechanistic models for the prediction of brain drug exposure and response in the paediatric population: A virtual child reaching maturation.

read more

Aerobe exercise has a positive effect on brain function in Parkinson's disease patients

18 January 2022

Radboudumc researchers have shown that the brain function of patients with Parkinson's disease improved with regular exercise, which seems to strengthen the connections between different brain areas, while inhibiting brain shrinkage.

read more

Last call for nominations for the RIHS Awards 2021 Deadline for submission is 25 January 2022

18 January 2022

RIHS researchers are invited to propose candidates for the RIHS PhD Award, the Societal Impact Award, the Science Award, the Supervisor of the Year Award, and the RIHS Patient Involvement Award.

read more

Cause of male infertility already present in DNA before birth

17 January 2022

New mutations in DNA, which are not inherited from the father or mother but arise spontaneously before or during fertilization, can cause infertility in men.

read more

Rogier Kievit and Geert Litjens both receive ERC Starting Grant of 1.5 million euros Board of Directors congratulates researchers on top grant

13 January 2022

Researchers Rogier Kievit and Geert Litjens were today festively welcomed by the Board of Directors, because of the ERC Starting Grants they both received. With these European top grants, they can each design an ambitious research project and put together their own research group.

read more

Improved AI will boost cancer research and cancer care Geert Litjens receives ERC Starting Grant

13 January 2022

Geert Litjens from Radboud university medical center has received a European Research Council (ERC) Starting Grant.

read more